August 8, 2017 / 11:26 AM / in 5 months

BRIEF-Rxi Pharmaceuticals says ‍selected two self-delivering RNAI compounds for preclinical development​

Aug 8 (Reuters) - Rxi Pharmaceuticals Corp

* Rxi Pharmaceuticals says ‍selected two self-delivering RNAI (SD-RXRNA) compounds from its immuno-oncology pipeline for preclinical development​

* Rxi Pharmaceuticals - ‍decision triggered selection of a manufacturing facility to initiate production of CGMP grade material, initially for RXI-762​

* Says to ‍move Rxi-762 into clinical development as early as 2018 as part of an ACT therapy​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below